Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF(V600) mutation-positive metastatic melanoma treated with vemurafenib +/- cobimetinib

Lewis, K; Hauschild, A; Larkin, J; Ribas, A; Flaherty, KT; McArthur, GA; Dreno, B; McKenna, E; Zhu, Q; Mun, Y; Ascierto, PA

Lewis, K (reprint author), Univ Colorado, Comprehens Canc Ctr, Div Med Oncol, 12605 E 16th Ave, Aurora, CO 80045 USA.

EUROPEAN JOURNAL OF CANCER, 2019; 116 (): 45

Abstract

Background: We conducted a retrospective analysis to evaluate the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the effica......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索